ANI Pharmaceuticals Inc (NASDAQ:ANIP) major shareholder Meridian Venture Partners Ii L sold 61,697 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $71.64, for a total transaction of $4,419,973.08. The transaction was disclosed in a filing with the SEC, which is available through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Meridian Venture Partners Ii L also recently made the following trade(s):
- On Friday, August 9th, Meridian Venture Partners Ii L sold 19,860 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $71.70, for a total transaction of $1,423,962.00.
Shares of NASDAQ:ANIP opened at $67.09 on Friday. The firm has a fifty day moving average price of $80.45 and a two-hundred day moving average price of $70.60. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.01 and a quick ratio of 0.74. ANI Pharmaceuticals Inc has a one year low of $36.92 and a one year high of $86.96. The company has a market cap of $847.24 million, a price-to-earnings ratio of 14.55 and a beta of 2.17.
ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported $1.44 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.18 by $0.26. ANI Pharmaceuticals had a net margin of 8.14% and a return on equity of 29.53%. The firm had revenue of $54.36 million during the quarter, compared to the consensus estimate of $55.20 million. During the same period last year, the firm earned $1.13 EPS. The business’s quarterly revenue was up 15.0% compared to the same quarter last year. Equities research analysts expect that ANI Pharmaceuticals Inc will post 5.29 EPS for the current fiscal year.
A number of large investors have recently made changes to their positions in ANIP. Tower Research Capital LLC TRC bought a new position in ANI Pharmaceuticals in the 2nd quarter valued at $32,000. Financial Gravity Wealth Inc. bought a new position in ANI Pharmaceuticals in the 1st quarter valued at $54,000. Quantamental Technologies LLC boosted its holdings in ANI Pharmaceuticals by 169.4% in the 1st quarter. Quantamental Technologies LLC now owns 862 shares of the specialty pharmaceutical company’s stock valued at $61,000 after purchasing an additional 542 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in ANI Pharmaceuticals by 237.9% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 794 shares of the specialty pharmaceutical company’s stock valued at $65,000 after purchasing an additional 559 shares during the period. Finally, Municipal Employees Retirement System of Michigan bought a new position in ANI Pharmaceuticals in the 4th quarter valued at $115,000. 64.22% of the stock is owned by hedge funds and other institutional investors.
Several research analysts recently commented on the stock. Raymond James downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and raised their price objective for the stock from $73.00 to $82.00 in a report on Friday, May 10th. Zacks Investment Research downgraded shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $89.00 price objective on shares of ANI Pharmaceuticals in a report on Thursday, May 9th. ValuEngine downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $90.00 price objective (up from $80.00) on shares of ANI Pharmaceuticals in a report on Monday, May 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. ANI Pharmaceuticals currently has an average rating of “Hold” and an average target price of $89.00.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.